Tranexamic Acid During Cystectomy Trial (TACT)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2021

Study Completion Date

June 30, 2021

Conditions
Bladder Cancer
Interventions
DRUG

Tranexamic Acid

Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).

DRUG

Placebo

As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.

Trial Locations (10)

T6G 1Z1

Northern Alberta Urology Centre, Edmonton

R2H 2A6

St. Boniface General Hospital, Winnipeg

B3H 2Y9

Queen Elizabeth II Health Sciences Centre, Halifax

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

N6A 4G5

London Health Sciences Complex (LHSC), London

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 2C4

University Health Network, Toronto

H3A 1A1

McGill University Health Centre (MUHC), Montreal

Unknown

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

G1R 3S1

Centre Hospitalier de l'Université de Québec (CHUQ), Québec

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Dalhousie University

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

collaborator

Laval University

OTHER

collaborator

University of Western Ontario, Canada

OTHER

collaborator

University Health Network, Toronto

OTHER

lead

Ottawa Hospital Research Institute

OTHER